BioLineRx Cost Of Revenue vs Total Revenue Analysis

BLRX Stock

USD 0.27 0.01 3.57%

BioLineRx financial indicator trend analysis is way more than just evaluating BioLineRx prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioLineRx is a good investment. Please check the relationship between BioLineRx Cost Of Revenue and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Cost Of Revenue vs Total Revenue

Cost Of Revenue vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioLineRx Cost Of Revenue account and Total Revenue. At this time, the significance of the direction appears to have almost identical trend.

The correlation between BioLineRx's Cost Of Revenue and Total Revenue is 0.94. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of BioLineRx, assuming nothing else is changed. The correlation between historical values of BioLineRx's Cost Of Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of BioLineRx are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Cost Of Revenue i.e., BioLineRx's Cost Of Revenue and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Cost Of Revenue

Cost of Revenue is found on BioLineRx income statement and represents the costs associated with goods and services BioLineRx provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Revenue

Total revenue comprises all receipts BioLineRx generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from BioLineRx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 22.8 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.05) in 2024.

BioLineRx fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity
Total Assets		-0.04	0.39	0.67	-0.14	0.56	-0.14	-0.5	0.79	0.66	0.74	0.17	0.41	0.74	0.66	0.65	0.61	0.63	0.65	0.51	-0.74	0.75	0.01	0.83	0.0	0.71
Other Current Liab	-0.04		0.54	-0.42	0.01	0.28	0.6	0.43	0.04	0.39	-0.35	-0.44	0.48	-0.07	0.39	-0.37	0.21	-0.47	0.42	0.04	-0.15	-0.09	-0.24	-0.19	0.38	0.25
Total Current Liabilities	0.39	0.54		-0.38	0.1	0.92	-0.12	-0.28	0.43	0.86	0.19	-0.2	0.97	0.38	0.85	0.31	0.74	0.2	0.79	0.64	-0.81	0.39	0.04	0.23	0.04	0.78
Total Stockholder Equity	0.67	-0.42	-0.38		-0.37	-0.19	-0.03	-0.24	0.34	-0.03	0.63	0.4	-0.39	0.31	-0.03	0.36	-0.08	0.43	0.05	-0.01	-0.03	0.32	-0.13	0.71	-0.05	0.02
Other Liab	-0.14	0.01	0.1	-0.37		0.15	0.23	-0.03	0.0	0.11	-0.45	-0.2	0.25	0.27	0.14	-0.04	0.17	-0.03	-0.05	-0.28	-0.24	0.25	0.45	-0.34	-0.45	0.37
Accounts Payable	0.56	0.28	0.92	-0.19	0.15		-0.24	-0.43	0.61	0.86	0.3	-0.14	0.94	0.63	0.86	0.51	0.87	0.44	0.76	0.7	-0.91	0.65	0.23	0.32	0.02	0.87
Cash	-0.14	0.6	-0.12	-0.03	0.23	-0.24		0.69	-0.18	-0.13	-0.59	-0.25	-0.14	-0.12	-0.11	-0.37	-0.21	-0.37	-0.09	-0.55	0.28	-0.14	0.06	-0.31	0.12	-0.09
Other Assets	-0.5	0.43	-0.28	-0.24	-0.03	-0.43	0.69		-0.43	-0.4	-0.6	-0.14	-0.33	-0.49	-0.4	-0.59	-0.47	-0.6	-0.33	-0.63	0.55	-0.5	-0.18	-0.46	0.18	-0.49
Long Term Debt	0.79	0.04	0.43	0.34	0.0	0.61	-0.18	-0.43		0.67	0.41	-0.32	0.52	0.9	0.67	0.46	0.81	0.44	0.65	0.58	-0.76	0.88	0.14	0.45	0.19	0.71
Common Stock Shares Outstanding	0.66	0.39	0.86	-0.03	0.11	0.86	-0.13	-0.4	0.67		0.44	-0.21	0.88	0.54	1.0	0.33	0.78	0.26	0.97	0.58	-0.92	0.54	-0.11	0.54	-0.11	0.92
Short Term Investments	0.74	-0.35	0.19	0.63	-0.45	0.3	-0.59	-0.6	0.41	0.44		0.48	0.15	0.25	0.43	0.51	0.23	0.49	0.49	0.49	-0.47	0.27	-0.35	0.94	-0.16	0.35
Other Current Assets	0.17	-0.44	-0.2	0.4	-0.2	-0.14	-0.25	-0.14	-0.32	-0.21	0.48		-0.25	-0.23	-0.21	0.32	-0.32	0.33	-0.21	-0.06	0.14	-0.19	-0.17	0.45	-0.14	-0.2
Total Liab	0.41	0.48	0.97	-0.39	0.25	0.94	-0.14	-0.33	0.52	0.88	0.15	-0.25		0.5	0.88	0.34	0.85	0.25	0.77	0.66	-0.87	0.51	0.13	0.19	0.03	0.85
Intangible Assets	0.74	-0.07	0.38	0.31	0.27	0.63	-0.12	-0.49	0.9	0.54	0.25	-0.23	0.5		0.55	0.61	0.82	0.61	0.43	0.5	-0.75	1.0	0.48	0.29	0.09	0.74
Common Stock	0.66	0.39	0.85	-0.03	0.14	0.86	-0.11	-0.4	0.67	1.0	0.43	-0.21	0.88	0.55		0.33	0.79	0.27	0.96	0.57	-0.93	0.55	-0.09	0.53	-0.11	0.93
Property Plant Equipment	0.65	-0.37	0.31	0.36	-0.04	0.51	-0.37	-0.59	0.46	0.33	0.51	0.32	0.34	0.61	0.33		0.54	0.97	0.2	0.58	-0.58	0.65	0.48	0.45	-0.14	0.49
Short Long Term Debt Total	0.61	0.21	0.74	-0.08	0.17	0.87	-0.21	-0.47	0.81	0.78	0.23	-0.32	0.85	0.82	0.79	0.54		0.5	0.67	0.77	-0.88	0.82	0.33	0.24	0.15	0.84
Property Plant And Equipment Net	0.63	-0.47	0.2	0.43	-0.03	0.44	-0.37	-0.6	0.44	0.26	0.49	0.33	0.25	0.61	0.27	0.97	0.5		0.15	0.52	-0.52	0.65	0.5	0.45	-0.17	0.45
Current Deferred Revenue	0.65	0.42	0.79	0.05	-0.05	0.76	-0.09	-0.33	0.65	0.97	0.49	-0.21	0.77	0.43	0.96	0.2	0.67	0.15		0.52	-0.83	0.43	-0.28	0.6	-0.06	0.82
Net Debt	0.51	0.04	0.64	-0.01	-0.28	0.7	-0.55	-0.63	0.58	0.58	0.49	-0.06	0.66	0.5	0.57	0.58	0.77	0.52	0.52		-0.68	0.52	0.09	0.33	0.25	0.53
Retained Earnings	-0.74	-0.15	-0.81	-0.03	-0.24	-0.91	0.28	0.55	-0.76	-0.92	-0.47	0.14	-0.87	-0.75	-0.93	-0.58	-0.88	-0.52	-0.83	-0.68		-0.75	-0.15	-0.51	0.16	-0.96
Non Current Assets Total	0.75	-0.09	0.39	0.32	0.25	0.65	-0.14	-0.5	0.88	0.54	0.27	-0.19	0.51	1.0	0.55	0.65	0.82	0.65	0.43	0.52	-0.75		0.49	0.32	0.08	0.74
Non Currrent Assets Other	0.01	-0.24	0.04	-0.13	0.45	0.23	0.06	-0.18	0.14	-0.11	-0.35	-0.17	0.13	0.48	-0.09	0.48	0.33	0.5	-0.28	0.09	-0.15	0.49		-0.36	-0.17	0.19
Cash And Short Term Investments	0.83	-0.19	0.23	0.71	-0.34	0.32	-0.31	-0.46	0.45	0.54	0.94	0.45	0.19	0.29	0.53	0.45	0.24	0.45	0.6	0.33	-0.51	0.32	-0.36		-0.22	0.47
Net Receivables	0.0	0.38	0.04	-0.05	-0.45	0.02	0.12	0.18	0.19	-0.11	-0.16	-0.14	0.03	0.09	-0.11	-0.14	0.15	-0.17	-0.06	0.25	0.16	0.08	-0.17	-0.22		-0.22
Common Stock Total Equity	0.71	0.25	0.78	0.02	0.37	0.87	-0.09	-0.49	0.71	0.92	0.35	-0.2	0.85	0.74	0.93	0.49	0.84	0.45	0.82	0.53	-0.96	0.74	0.19	0.47	-0.22

Click cells to compare fundamentals

BioLineRx Account Relationship Matchups

BioLineRx fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	53.6M	47.3M	81.4M	76.4M	63.9M	53.7M
Other Current Liab	7K	1.4M	1.2M	1.3M	3.4M	3.5M
Total Current Liabilities	12.0M	10.6M	9.7M	10.7M	30.9M	32.4M
Total Stockholder Equity	33.4M	22.0M	68.1M	50.8M	13.2M	12.6M
Other Liab	323K	658K	10.2M	1.9M	2.1M	2.2M
Accounts Payable	7.8M	5.9M	5.6M	7.0M	10.9M	11.4M
Cash	5.3M	16.8M	13.0M	10.6M	4.3M	8.0M
Long Term Debt	7.8M	5.8M	2.7M	8.6M	6.6M	3.6M
Common Stock Shares Outstanding	9.8M	16.9M	44.2M	51.6M	64.2M	67.4M
Short Term Investments	22.2M	5.8M	44.1M	40.5M	38.7M	28.6M
Other Current Assets	108K	152K	127K	198K	1.5M	1.5M
Total Liab	20.2M	25.3M	13.3M	25.5M	50.7M	53.2M
Intangible Assets	21.9M	21.7M	21.7M	21.9M	14.9M	10.4M
Common Stock	4.7M	9.9M	21.1M	27.1M	31.4M	32.9M
Property Plant Equipment	2.2M	3.5M	2.7M	2.3M	2.6M	2.1M
Short Long Term Debt Total	10.5M	7.7M	4.7M	12.3M	11.6M	12.2M
Property Plant And Equipment Net	3.5M	2.7M	2.3M	2.5M	1.9M	2.2M
Net Debt	5.2M	(9.1M)	(8.3M)	1.7M	7.3M	7.7M
Retained Earnings	(248.0M)	(278.0M)	(305.0M)	(330.0M)	(390.6M)	(371.1M)
Non Current Assets Total	25.4M	24.4M	24.0M	24.4M	16.7M	13.7M
Non Currrent Assets Other	56K	25.4M	21.4M	(1.0)	(1.15)	(1.09)
Cash And Short Term Investments	27.5M	22.6M	57.1M	51.1M	43.0M	39.3M
Net Receivables	613K	141K	142K	721K	708K	430.0K
Common Stock Total Equity	2.8M	3.1M	4.7M	9.9M	11.4M	11.9M
Liabilities And Stockholders Equity	53.6M	47.3M	81.4M	76.4M	63.9M	54.1M
Non Current Liabilities Total	8.2M	14.6M	3.6M	14.9M	19.8M	20.8M
Other Stockholder Equity	265.9M	279.2M	339.3M	339.0M	355.5M	255.4M
Property Plant And Equipment Gross	3.5M	2.7M	6.8M	2.5M	7.4M	7.8M
Total Current Assets	28.2M	22.9M	57.4M	52.0M	47.2M	40.4M
Accumulated Other Comprehensive Income	10.7M	10.9M	11.7M	13.3M	17.0M	10.8M
Short Term Debt	2.9M	3.3M	2.9M	2.4M	3.7M	3.9M
Net Tangible Assets	19.3M	11.5M	316K	46.4M	41.7M	22.1M
Short Long Term Debt	2.7M	3.1M	2.8M	1.5M	3.1M	1.8M
Net Invested Capital	41.9M	27.9M	70.8M	61.0M	23.0M	37.5M
Net Working Capital	16.2M	12.2M	47.7M	41.3M	16.3M	23.2M
Capital Stock	4.7M	9.9M	21.1M	27.1M	31.4M	17.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioLineRx Cost Of Revenue vs Total Revenue Analysis

Cost Of Revenue vs Total Revenue

Cost Of Revenue vs Total Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Total Revenue

BioLineRx fundamental ratios Correlations

BioLineRx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioLineRx fundamental ratios Accounts

Also Currently Popular

Additional Tools for BioLineRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Non Current Assets Total	+ 1.0	Intangible Assets
Total Liab	+ 0.97	Total Current Liabilities
Current Deferred Revenue	+ 0.97	Common Stock Shares Outstanding
Property Plant And Equipment Net	+ 0.97	Property Plant Equipment
Current Deferred Revenue	+ 0.96	Common Stock

Common Stock Total Equity	- 0.96	Retained Earnings
Retained Earnings	- 0.93	Common Stock
Retained Earnings	- 0.92	Common Stock Shares Outstanding
Retained Earnings	- 0.91	Accounts Payable
Retained Earnings	- 0.88	Short Long Term Debt Total
Retained Earnings	- 0.87	Total Liab